vs

Side-by-side financial comparison of Immunovant, Inc. (IMVT) and PURE CYCLE CORP (PCYO). Click either name above to swap in a different company.

PURE CYCLE CORP is the larger business by last-quarter revenue ($9.1M vs $8.4M, roughly 1.1× Immunovant, Inc.). PURE CYCLE CORP runs the higher net margin — 50.0% vs -899.0%, a 949.0% gap on every dollar of revenue. On growth, Immunovant, Inc. posted the faster year-over-year revenue change (140.7% vs 58.8%).

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.

Pure Cycles, is a bicycle company based in Los Angeles, California that was founded by Michael Fishman, Jordan Schau, Zachary Schau and Austin Stoffers in 2010, as Pure Fix Cycles.

IMVT vs PCYO — Head-to-Head

Bigger by revenue
PCYO
PCYO
1.1× larger
PCYO
$9.1M
$8.4M
IMVT
Growing faster (revenue YoY)
IMVT
IMVT
+81.9% gap
IMVT
140.7%
58.8%
PCYO
Higher net margin
PCYO
PCYO
949.0% more per $
PCYO
50.0%
-899.0%
IMVT

Income Statement — Q4 FY2024 vs Q1 FY2026

Metric
IMVT
IMVT
PCYO
PCYO
Revenue
$8.4M
$9.1M
Net Profit
$-75.3M
$4.6M
Gross Margin
68.4%
Operating Margin
-896.2%
48.0%
Net Margin
-899.0%
50.0%
Revenue YoY
140.7%
58.8%
Net Profit YoY
-26.7%
16.0%
EPS (diluted)
$-0.50
$0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMVT
IMVT
PCYO
PCYO
Q4 25
$9.1M
Q3 25
$11.2M
Q2 25
$5.1M
Q1 25
$4.0M
Q4 24
$5.8M
Q3 24
$12.6M
Q2 24
$7.6M
Q1 24
$8.4M
$3.2M
Net Profit
IMVT
IMVT
PCYO
PCYO
Q4 25
$4.6M
Q3 25
$6.1M
Q2 25
$2.3M
Q1 25
$809.0K
Q4 24
$3.9M
Q3 24
$6.6M
Q2 24
$2.8M
Q1 24
$-75.3M
$118.0K
Gross Margin
IMVT
IMVT
PCYO
PCYO
Q4 25
68.4%
Q3 25
67.7%
Q2 25
63.4%
Q1 25
38.2%
Q4 24
63.8%
Q3 24
77.8%
Q2 24
64.0%
Q1 24
55.6%
Operating Margin
IMVT
IMVT
PCYO
PCYO
Q4 25
48.0%
Q3 25
53.1%
Q2 25
26.0%
Q1 25
-33.2%
Q4 24
29.9%
Q3 24
62.0%
Q2 24
40.3%
Q1 24
-896.2%
-11.5%
Net Margin
IMVT
IMVT
PCYO
PCYO
Q4 25
50.0%
Q3 25
54.5%
Q2 25
43.9%
Q1 25
20.3%
Q4 24
68.4%
Q3 24
52.6%
Q2 24
37.2%
Q1 24
-899.0%
3.7%
EPS (diluted)
IMVT
IMVT
PCYO
PCYO
Q4 25
$0.19
Q3 25
$0.26
Q2 25
$0.09
Q1 25
$0.03
Q4 24
$0.16
Q3 24
$0.27
Q2 24
$0.12
Q1 24
$-0.50
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMVT
IMVT
PCYO
PCYO
Cash + ST InvestmentsLiquidity on hand
$635.4M
$17.1M
Total DebtLower is stronger
$8.0M
Stockholders' EquityBook value
$617.8M
$147.5M
Total Assets
$666.4M
$168.1M
Debt / EquityLower = less leverage
0.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMVT
IMVT
PCYO
PCYO
Q4 25
$17.1M
Q3 25
$21.9M
Q2 25
$14.4M
Q1 25
$16.5M
Q4 24
$19.0M
Q3 24
$22.1M
Q2 24
$20.5M
Q1 24
$635.4M
$20.6M
Total Debt
IMVT
IMVT
PCYO
PCYO
Q4 25
$8.0M
Q3 25
$6.8M
Q2 25
$6.9M
Q1 25
$6.9M
Q4 24
$6.9M
Q3 24
$6.9M
Q2 24
Q1 24
Stockholders' Equity
IMVT
IMVT
PCYO
PCYO
Q4 25
$147.5M
Q3 25
$142.7M
Q2 25
$136.7M
Q1 25
$134.4M
Q4 24
$133.6M
Q3 24
$129.7M
Q2 24
$123.2M
Q1 24
$617.8M
$120.4M
Total Assets
IMVT
IMVT
PCYO
PCYO
Q4 25
$168.1M
Q3 25
$162.3M
Q2 25
$151.7M
Q1 25
$149.7M
Q4 24
$149.7M
Q3 24
$147.4M
Q2 24
$140.4M
Q1 24
$666.4M
$135.2M
Debt / Equity
IMVT
IMVT
PCYO
PCYO
Q4 25
0.05×
Q3 25
0.05×
Q2 25
0.05×
Q1 25
0.05×
Q4 24
0.05×
Q3 24
0.05×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMVT
IMVT
PCYO
PCYO
Operating Cash FlowLast quarter
$-59.7M
$-979.0K
Free Cash FlowOCF − Capex
$-59.8M
FCF MarginFCF / Revenue
-714.4%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
-0.21×
TTM Free Cash FlowTrailing 4 quarters
$-214.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMVT
IMVT
PCYO
PCYO
Q4 25
$-979.0K
Q3 25
$9.4M
Q2 25
$-503.0K
Q1 25
$-1.4M
Q4 24
$5.7M
Q3 24
$3.1M
Q2 24
$892.0K
Q1 24
$-59.7M
$-457.0K
Free Cash Flow
IMVT
IMVT
PCYO
PCYO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$-59.8M
FCF Margin
IMVT
IMVT
PCYO
PCYO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-714.4%
Capex Intensity
IMVT
IMVT
PCYO
PCYO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
1.8%
Cash Conversion
IMVT
IMVT
PCYO
PCYO
Q4 25
-0.21×
Q3 25
1.53×
Q2 25
-0.22×
Q1 25
-1.70×
Q4 24
1.44×
Q3 24
0.47×
Q2 24
0.32×
Q1 24
-3.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IMVT
IMVT

Segment breakdown not available.

PCYO
PCYO

Construction$6.5M71%
Water And Wastewater Resource Development Segment$2.5M27%

Related Comparisons